Lipoprotein(a) and proliferative diabetic retinopathy in Type II diabetes mellitus: A role for isoforms with low molecular weight

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 9, Issue 3, 1996, Pages 129-137

  Buscaglia, P ^a   Gazzaruso, C ^a   Garzaniti, A ^a   Bonetti, G ^a   Porta, A ^a   Negri, A ^a   Vandelli, G ^a   Finardi, G ^a   Fratino, P ^a   Geroldi, D ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Apo(a) isoforms; Diabetic retinopathy; Lipoprotein(a); Microangiopathy

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; PLASMINOGEN;

ADULT; ARTICLE; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; GENETIC HETEROGENEITY; GENETIC RISK; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

EID: 8944258550     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Klein R., Klein B.E.K., Moss S.E., Davis M.D., DeMets D.L.: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 102: 520-526, 1984.
2. Klein R., Klein B.E.K., Moss S.E., Davis M.D., DeMets D.L.: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch. Ophthalmol. 102: 527-532, 1984.
3. The Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986, 1993.
4. Klein R., Klein B.E.K., Moss S.E., Cruickshanks K.J.: Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch. Int. Med. 154: 2169-2178, 1994.
5. Stewart L.L., Field L.L., Ross S., McArthur R.G.: Genetic risk factors in diabetic retinopathy. Diabetologia 36: 1293-1298, 1993.
6. Berg K.: A new serum type system in man. The Lp(a) system. Acta Pathol. Microbiol. Scand. 59: 369-382, 1963.
7. Loscalzo J.: Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 10: 672-673, 1990.
8. Csaszar A., Dieplinger H., Sandholzer C., Karadi I., Juhasz E., Drexel H., Halmos T., Romics L., Patsch J.R., Utermann G.: Plasma lipoprotein(a) concentration in diabetes mellitus. Diabeiologia 36:41-51, 1993.
9. Guillausseau P.-J., Peynet J., Chanson P., Legrand A., Altman J.-J., Puopon J., N'Guyen M., Rousselet F., Lubetzki J.: Lipoprotein(a) in diabetic patients with and without chronic renal failure. Diabetes Care 15: 976-979, 1992.
10. Haffner S.M., Tuttle K.R., Rainwater D.L.: Decrease of Lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care 14: 302-307, 1992.
11. Nakata H., Kazutoshi H., Masaaki E.: Alteration of Lipoprotein(a) concentration with glycemic control in non insulindependent diabetic subjects without diabetic complication. Metabolism 42: 1323-1326, 1993.
12. Haffner S.M., Tuttle K.R., Rainwater D.L.: Lack of change of Lipoprotein(a) concentration with improved glycemic control in subjects with type II diabetes. Metabolism 41: 116-120, 1992.
13. Maioli, M., Tonolo G., Pacifico A., Ciccarese M., Brizzi P., Konner E.M., Porta M., Raised serum apolipoprotein(a) in active diabetic retinopathy. Diabetologia 36: 88-90, 1993.
14. Heshmati H.M., Cohen R., Legrand M., Baudin E., Fernere F., Torregrossa M.L., Modigliani E.: Liens entre la lipoproteine (a) et les complications vasculaires du diabète [Letter]. La Presse Medicale 31: 1461, 1993.
15. Utermann G., Duba C. Menzel H.J.: Genetics of the quantitative Lp(a) lipoprotein trait. II Inheritance of the Lp(a) glycoprotein phenotypes. Hum. Genet. 78: 47-50, 1988.
16. Ilyas Kamboh M., Ferrel R.E., Kottke B.A.: Expressed hypervariable polymorphism of apolipoprotein(a). Am. J. Hum. Genet 49: 1063-1064, 1991.
17. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057, 1979.
18. 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. ISH Hypertension News Special Edition. June: 3-16, 1993.
19. Diabetic Retinopathy Study Research Group, Report 7: A modification of the Airlie House classification of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 21: 210-226, 1981.
20. The Diabetes Control and Complication Trial Research Group: Color photography vs fluorescein angiography in the detection of diabetic retinopathy in the Diabetes Control and Complication Trial. Arch, Ophthalmol. 105: 1344-1351, 1987.
21. Friedewald W.T., Levy R.I., Fredrickson D.S.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentifuge. Clin. Chem. 18: 499-502, 1972.
22. Geroldi D., Bellotti V., Buscaglia P., Bonetti G., Gazzaruso C., Caprioli A., Fratino P.: Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin. Chim. Acta 221: 159-169, 1993.
23. Sandholzer C., Boerwinkle E., Saha N., Tong M.C., Utermann G.: Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J. Clin. Invest. 89: 1040-1046, 1992.
24. Utermann G., Kraft H.G., Menzel H.J., Hopferwieser T., Seitz C.: Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentration in plasma. Hum. Genet. 78: 41-46, 1988.
25. Rainwater D.L., MacCluer J.W., Stern M.P., VandeBerg J.L., Haffner S.M.: Effects of NIDDM on Lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes 43: 942-946, 1994.
26. Geroldi D., Gazzaruso C., Garzaniti A., Buscaglia P., Bonetti G., Auguadro C., Chioffi M., Falcone C., Bobbio-Pallavicini E., Fratino P., Finardi G.: Apo(a) isoforms: a genetic marker for progression of coronary atherosclerosis [Abstract]. Atherosclerosis 109: 283, 1994.
27. Buscaglia P., Gazzaruso C., Garzaniti A., Bonetti G., Fratino P., Geroldi D.: Lipoprotein(a), apo(a) polymorphism and insulin treatment in type 2 diabetic patients [Letter]. Diabetes Care 18: 1202-1203, 1995.
28. Buscaglia P., Gazzaruso C., Garzaniti A., Bonetti G., Porta A., Fratino P., Vandelli G., Geroldi D.: Lp(a) concentration and apo(a) isoforms in type 2 diabetic patients with and without diabetic retinopathy. G. Ital. Diabetol. 15 (Suppl.): 24-25, 1995.
29. Gazzaruso C., Buscaglia P., Garzaniti A., Bonetti G., Savino S., Mariotti S., Jucci A., Finardi G., Geroldi D.: Lp(a) plasma concentration, apo(a) polymorphism and family history of coronary heart disease in patients with essential hypertension. J. Cardiovasc. Risk (in press).
30. Steno Study Group: Effect of 6 months of strict metabolic control on eye and kidney function in insulin-dependent diabetics with background retinopathy. Lancet I: 121-124, 1982.
31. Marshall G., Garg S.K., Jackson W.E., Holmes D.L., Chase H.P.: Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 100: 1133-1139, 1993.
32. UKPDS Group Prospective Diabetes Study: Complications in newly diagnosed type 2 patients and their association with clinical and biochemical risk factor. Diabetes Res. 13: 1-11, 1990.
33. Buscaglia P., Gazzaruso C., Garzaniti A., Bonetti G., Porta A., Fratino P., Vandelli G., Geroldi D.: Lp(a) concentration and apo(a) isoforms in type 2 diabetic patients with and without diabetic retinopathy [Abstract]. Eur. J. Ophthalmol. 4: 245, 1994.
34. Sandholzer C., Saha N., Kark J.D., Rees A., Jaross W., Dieplinger H., Hoppichler F., Boerwinkle E., Utermann G.: Apo(a) isoforms predict risk for Coronary Heart Disease. A study in six populations. Arierio. Thromb. 12: 1214-1226, 1992.
35. Durrington P.N., Ishola M., Hunt L., Arrol S., Bhatnagar D.: Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet I: 1070-1073, 1988.
36. Frank S.L., Klisak I., Sparkes R.S., Mohandas T., Tomlinson J.E., McLean J.W., Lawn R.M., Lusis A.J.: The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. Hum. Genet. 79: 352-356, 1988.
37. Gonzales-Gronow M., Edelberg J.M., Pizzo S.V.: Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry 28: 2374-2377, 1989.
38. Edelberg J.M., Pizzo S.V.: Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. Biochemistry 29: 5906-5913, 1990.
39. Etingin O.R., Hajjar O.P., Harpel P.C., Nachmann R.L.: Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J. Biol. Chem. 226: 2459-2465, 1991.
40. Di Minno G., Silver M.J., Cerbone A.M., Riccardi G., Rivellese A., Mancini M.: Platelet fibrinogen binding in diabetes mellitus differences between binding to platelets from nonretinopathic and retinopathic diabetic patients. Diabetes 35: 182-185, 1986.
41. Lorenzi M., Cagliero E.: Pathobiology of endothelial and other vascular cells in diabetes mellitus: call for data. Diabetes 40: 653-659, 1991.
42. Boerwinkle E.: Genetics of plasma lipoprotein(a) concentrations. Curr. Op. Lipid. 3: 128-136, 1992.